p53 gene alterations correlate highly with advanced ovarian carcinoma in women. In mice, p53 deficiency predominantly results in the formation of lymphomas and sarcomas. However, ovarian epithelial tumors have not been documented in p53 homozygous mutant (p53 À/À ) mice, probably because they die before other tumors can form. To determine whether p53 À/À ovaries can develop epithelial tumors, they were transplanted into the ovarian bursae of histocompatible wild-type recipient females. The p53 À/À ovarian grafts formed tumors B1 year posttransplantation. The tumor type was angiosarcoma, suggesting that vascular tissues are predisposed to tumor formation in p53 À/À ovaries. These findings suggest that p53 deficiency alone is not sufficient for ovarian epithelial tumorigenesis in mice. Thus, other genetic lesions are likely required to develop mouse models of human ovarian cancer.
Ovarian cancer is the second most prevalent cause of cancer-related death and the fifth leading cancer among American women (Jemal et al., 2003) . Approximately 90% of human ovarian cancer is derived from the ovarian epithelium (Auersperg et al., 2001) . Genetic alterations of oncogenes and tumor suppressor genes correlate with ovarian cancer formation and progression (Bast and Mills, 2000) . Among these genetic alterations, p53 mutations are the most common in advanced ovarian cancer (for review, see Shelling et al., 1995; Schuijer and Berns, 2003) . In contrast, p53 gene alterations are infrequent in benign ovarian tumors or the early stages of ovarian cancer. These findings suggest that p53 mutations play important roles in human ovarian cancer progression.
Several strains of p53 knockout mice have been created by gene targeting in mouse embryonic stem cells (Donehower et al., 1992; Jacks et al., 1994; Purdie et al., 1994) . p53 À/À mice spontaneously develop a spectrum of tumors that depends in part upon genetic background (Venkatachalam et al., 2002) . The tumor latency for p53 À/À mice is generally B6-8 months of age. Lymphomas and sarcomas are the primary tumor types on C57Bl/6 Â 129 (B6/129) mixed and C57Bl/6 inbred genetic backgrounds (Venkatachalam et al., 2002) . Carcinoma incidence in p53 À/À mice is relatively rare. The incidence of ovarian tumors in p53 À/À mice has not been reported, most likely because other types of cancer cause lethality before these tumors might arise. Given sufficient time, it seems reasonable to imagine that p53 mutant ovaries should be able to form tumors. Therefore, we used the classic technique of ovary transplantation into histocompatible wild-type female hosts to avoid the lethal tumor-burden that develops in p53
The ovaries of 3-to 5-week-old p53 À/À mice on a C57Bl/6J (B6) congenic background (Jackson Laboratory, Bar Harbor, ME, USA) were removed and onehalf of each ovary was transplanted into the ovarian bursa of ovariectomized age-matched histocompatible C57Bl/6J (B6) inbred or B6/129F1 hybrid mice ( Figure 1a ). p53 þ /À ovaries were transplanted, which served as controls. Subsequently, ovarian tumor formation was monitored by palpating the abdomen of the recipient females twice per week. However, at 11 months post-transplantation, we were only able to identify one case of tumor formation by abdominal palpation. Therefore, we examined p53 À/À ovarian grafts at 7-8 and at 11-13 months post-transplantation (Table 1) . p53 À/À ovarian grafts were grossly normal in appearance up to 7-8 months post-transplantation, consistent with the lack of spontaneous ovarian tumor formation in p53 À/À mice ( Figure 1c ). However, by 11-13 months post-transplantation, all successfully transplanted p53 Histological analysis of the malignant tumors indicated angiosarcoma (Turusov and Mohr, 1994; Mohr, 2001) . Therefore, CD34 immunohistochemistry was performed to confirm the endothelial identity of vessels in the p53 À/À ovarian tumors. The p53 À/À ovarian tumors showed moderate to strong CD34 immunostaining (Figure 2e and f). Interestingly, the two cystic appearing p53 À/À ovarian grafts had pleiomorphic hyperplastic cells showing CD34-positive immunostaining, suggesting that they were premalignant (Figure 2g -j). All of p53 À/À ovarian grafts developed CD34-positive neoplasms by 13 months in this study. p53 þ /À and p53 À/À ovarian grafts at 7-8 months showed CD34 immunostaining specifically localized to endothelial cells of vessels and a subset of cells surrounding ovarian follicles (Figure 2d and data not shown). Thus, there is a transition between these two time points when p53 À/À endothelial cells progress to malignancy. We also performed immunohistochemistry for asmooth muscle actin (a-SMA), cytokeratin 8 (CK8), À/À (e, f) ovary grafts at 13 months post-transplantation. p53 À/À ovarian tumors can be identified grossly showing cystic (blue arrows), pale (black arrow), and hemorrhagic (red arrow) appearances. Bar, 1 cm. Methods: B6 p53 þ /À or p53 À/À ovaries were transplanted into the ovarian bursae of B6 or B6129F 1 histocompatible recipient females that had had their endogenous ovaries removed as described (Nagy et al., 2003) Ovarian grafts were examined at 7-8 or 11-13 months post-transplantation. Mo, months and anti-Mu¨llerian hormone (AMH), markers that are expressed in different subsets of ovarian tissues. a-SMA is expressed in vascular smooth muscle cells and myofibroblasts of external theca layer of ovarian follicle (Figure 3a) . Vascular smooth muscle cells in the tumors showed positive immunostaining for a-SMA (Figure 3b) . The majority of the neoplastic cells in the p53 À/À ovarian tumors were a-SMA negative or had scattered positive staining cells perhaps due to tissue repair or the stromal response to neoplasia (Figure 3b and c) . CK8 is expressed specifically in the ovarian surface epithelium (Figure 3d ). We found that p53 À/À ovarian tumors were lined by a single cell layer (Figure 3e ) or focal invaginations of the ovarian surface epithelium that were CK8 positive (Figure 3f) . However, the neoplastic cells were CK8 negative. We also examined cell proliferation using Ki67 immunohistochemistry to examine whether the focal invaginations of the ovarian surface epithelium had malignant potential. We only found very few Ki67-positive cells in the focal invaginated area (Figure 3f , inset) similar to the normal appearing ovarian surface epithelium (data not shown). The most prominent Ki67-positive cells were neoplastic cells with giant or bizarre nuclei. Approximately, 50-70% of the neoplastic cells were Ki67 positive in comparison to 5-10% of the ovarian stromal cells that were Ki67 positive except for granulosa cells that were well labeled by Ki67 (data not shown). Moreover, AMH is expressed in granulosa cells of developing follicles (Figure 3g ). The remaining granulosa cells of the ovarian tumors were AMH positive, but the neoplastic cells were AMH negative (Figure 3h and i) .
Our studies show that B6 p53 À/À ovarian grafts consistently develop angiosarcoma after B1 year posttransplantation rather than epithelial malignancy. Interestingly, p53 gene mutations are associated with human angiosarcoma (Naka et al., 1997; Zietz et al., 1998) . Thus, our findings provide direct evidence for p53 deficiency in the development of angiosarcoma. Ovarian angiosarcomas are extremely rare in humans. Histopatholgical characteristics of ovarian angiosarcomas are similar to angiosarcomas arising from other soft tissues although the histological appearances may vary. These tumors consist of irregular vascular channels lined by anaplastic cells with pleiomorphic nuclei with a high frequency of mitotic figures (Nucci et al., 1998 , Platt et al., 1999 . Factor VIII, CD34, or CD31 expression in the neoplastic cells identifies them as vascular tissue (Nucci et al., 1998; Jylling et al., 1999) . Human ovarian angiosarcomas are highly aggressive with poor prognosis.
There are numerous transgenic and knockout mice that die at birth or before ovarian tumor formation, hampering the generation of mouse models for ovarian carcinoma. Homotopic or heterotopic transplantation of ovaries from neonates or older females into histocompatible recipients provides a way to circumvent premature mutant lethality (Chen and Behringer, 2004) . The ovary transplantation approach used in this study provides fundamental information regarding the latency and tumor spectrum of p53 À/À ovarian tumors. In agreement with recent reports (Orsulic et al., 2002; Flesken-Nikitin et al., 2003) , p53 deficiency alone does not seem to be sufficient for ovarian epithelial malignancy. However, p53 deficiency with activated Akt, cMyc, and K-ras pathways (Orsulic et al., 2002) or an inactivated retinoblastoma pathway (Flesken-Nikitin et al., 2003) leads to the transformation of the ovarian epithelium in mice. Our studies were performed on a B6 congenic background. It is possible that p53 deficiency on a different genetic background may lead to the formation of ovarian epithelial tumors. Interestingly, p53 heterozygous and homozygous mutant mice examined on a BALB/c genetic background develop mammary carcinoma (Kuperwasser et al., 2000; Blackburn et al., 2003) . Ovarian cancer incidence in p53-BALB/c mice has not been reported. Taken together, our findings are consistent with the idea that multiple genetic lesions and genetic modifiers coordinate with loss of p53 in the tumorigenesis of the ovarian surface epithelium. 
